Outcomes of women with atypical glandular cells on preoperative cytology and endometrial cancer

International Journal of Gynecological Cancer

Volumn 24, Issue 2, 2014, Pages 266-271

  Guy, Michael S ^a   Cheng, Georgina ^a   Post, Miriam D ^a   Spillman, Monique A ^a   Behbakht, Kian ^a   Davidson, Susan ^a   Sheeder, Jeanelle ^a   Guntupalli, Saketh R ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical glandular cells; Atypical glandular cells of undetermined significance; Cervical cytologic diagnosis; Endometrial cancer; Papanicolaou test

Indexed keywords

CA 125 ANTIGEN;

ADULT; ARTICLE; BODY MASS; CANCER CELL; CANCER CYTODIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM CYTOLOGY; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OUTCOME VARIABLE; PRIORITY JOURNAL; RACE;

ADENOCARCINOMA; AGED; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84893767659     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000027     Document Type: Article

References (21)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Boronow RC, Morrow CP, Creasman WT, et al. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol. 1984;63:825-832.
3. Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer. 1987;60:2035-2041.
4. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744-751.
5. Guntupalli SR, Zighelboim I, Kizer NT, et al. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. Gynecol Oncol. 2012;124:31-35.
6. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100:1707-1716.
7. Kitchener H, Swart AM, Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373:125-136.
8. Abu-Rustum NR, Alektiar K, Iasonos A, et al. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol. 2006;103:714-718.
9. Conte M, Panici PB, Guariglia L, et al. Pelvic lymphocele following radical para-aortic and pelvic lymphadenectomy for cervical carcinoma: incidence rate and percutaneous management. Obstet Gynecol. 1990;76:268-271.
10. Larson DM, Johnson K, Olson KA. Pelvic and para-aortic lymphadenectomy for surgical staging of endometrial cancer: morbidity and mortality. Obstet Gynecol. 1992;79:998-1001.
11. Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. 1941. Arch Pathol Lab Med. 1997;121:211-224.
12. Marques JP, Costa LB, Pinto AP, et al. Atypical glandular cells and cervical cancer: systematic review. Rev Assoc Med Bras. 2011;57:234-238.
13. Geier CS, Wilson M, Creasman W. Clinical evaluation of atypical glandular cells of undetermined significance. Am J Obstet Gynecol. 2001;184:64-69.
14. Larson DM, Johnson KK, Reyes CN, et al. Prognostic significance of malignant cervical cytology in patients with endometrial cancer. Obstet Gynecol. 1994;84:399-403.
15. Larson DM, Johnson KK, Broste SK, et al. Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer. Obstet Gynecol. 1995;86:38-42.
16. Sood AK, Buller RE, Burger RA, et al. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol. 1997;90:441-447.
17. Announcements. FIGO stages - 1988 revisions. Gynecol Oncol. 1989;35:125-127.
18. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009;105:109.
19. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377-381.
20. Lewin SN, Herzog TJ, Barrena Medel NI, et al. Comparative performance of the 2009 International Federation of Gynecology and Obstetrics' staging system for uterine corpus cancer. Obstet Gynecol. 2010;116:1141-1149.
21. Kinde I, Bettegowda C, Wang Y, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013;5:167ra4.